Key result
COVID-19 infection linked to smooth muscle protein downregulation correlating with troponin elevation.
Why the study?
Troponin elevation, exemplified by COVID-19, could reflect systemic vascular injury, which may refine the interpretation of cardiac biomarkers in viral illness.
Cohort (n=315)
Yes
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
In patients hospitalized with COVID-19, troponin elevation correlates with downregulation of smooth muscle myosin light chain proteins and elevated vascular injury markers, suggesting it reflects systemic vascular injury rather than direct myocardial injury.
BACKGROUND: Raised cardiac troponin-I is a common finding in patients hospitalised with acute viral infections, including but not limited to COVID-19. This often occurs in the absence of overt myocardial injury presenting a challenge for interpretation. The mechanisms underlying troponin elevation are uncertain. METHODS: The CISCO-19 (Cardiovascular Imaging in SARS-CoV-19) study (NCT04403607) is a prospective, multicentre cohort study, in which hospitalised PCR-confirmed COVID-19 participants (N=267) underwent multisystem evaluation at enrolment and at 28-60 days. The study incorporated plasma proteomics (SOMAscan V.4.1), cardiovascular MRI and clinical biomarkers. Of these, 211 had baseline plasma proteomic data and 185 completed follow-up sampling. Matched proteomic and imaging data were available for 155 participants (mean age: 55 years (SD 12); 43% female). RESULTS: A high likelihood of myocarditis was identified in 13.2% (N=21/159) of participants. High-sensitivity troponin-I was modestly elevated at enrolment (median 3 ng/L; IQR 2-6; n=159). Among males (n=90), 9.3% had a high-sensitivity troponin that exceeded 34 ng/L. Among females (n=69), 4.5% exceeded 16 ng/L. Smooth muscle myosin light chain proteins were downregulated at follow-up (log2 fold change -0.12 to -0.6; all adjusted p<0.02) and positively correlated with high-sensitivity troponin-I, but not N-terminal brain natriuretic peptide or cardiac MRI indices (n=155). CONCLUSIONS: Troponin elevation, exemplified here by COVID-19, could reflect systemic vascular injury. Recognising this mechanism may refine interpretation of cardiac biomarkers in viral illness and supports the investigation of vascular injury in future therapeutic strategies and biomedical studies.
Kamdar et al. (2026) conducted a cohort in COVID-19 (n=315). COVID-19 infection vs. Uninfected controls was evaluated on Diagnosis of myocarditis based on the modified Lake Louise criteria. COVID-19 infection was associated with downregulation of smooth muscle myosin light chain proteins at follow-up, which positively correlated with high-sensitivity troponin-I, suggesting troponin elevation may reflect systemic vascular injury.
Synapse has enriched 10 related papers. Consider them for comparative context: